A Comparison of Immediate Changes in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome

Trial Profile

A Comparison of Immediate Changes in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Poractant alfa (Primary)
  • Indications Neonatal respiratory distress syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2017 According to Cornerstone Pharmaceuticals media release, Cornerstone Pharmaceuticals changed name to Rafael Pharmaceuticals
    • 10 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top